@FierceMedDev: Volcano grabs ArtheroMed for up to $130M. News | Follow @FierceMedDev
@VarunSaxena2: RT from FierceMedicalDevices: FDA says recalled pediatric nasal prongs potentially deadly. Story | Follow @VarunSaxena2
@MichaelGFierce: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. FierceDrugDelivery story | Follow @MichaelGFierce
@EmilyWFierce: $PFE, $FRX and $LLY dominate top 10 ranking of psych meds. More from FiercePharmaMarketing | Follow @EmilyWFierce
> Valeant ($VRX), owner of Bausch + Lomb, increased its offer for Allergan ($AGN) to about $49.4 billion, or $166 per share. News
> The FDA has released new guidelines on how companies can request exceptions from the unique device identifier rule. More
Biotech News
@FierceBiotech: Turn on, tune in, tweet out for upcoming chat on CAR-T with @JohnCFierce & @PennMedicine's David Porter. #FierceASCO. Editor's Corner | Follow @FierceBiotech
@JohnCFierce: Fast biotech -- Upstart Spark grabs a $73M round to back rapid expansion, PhIII study - gene therapy. News | Follow @JohnCFierce
@DamianFierce: Per @Real_MNA, Stryker not bidding on Smith & Nephew but reserves right to do so within 6 mths. Palpable excitement for more UK takeover confusion. | Follow @DamianFierce
@EmilyMFierce: Pace of new MERS infections in Saudi Arabia slows to four a day. More from Reuters | Follow @EmilyMFierce
> Bayer taps Dutch antibody specialist for biologics discovery. More
> Slumping Array aligns with Biogen on early autoimmune R&D. Article
> Valeant dials up its Allergan bid and throws in some R&D promises. Story
> Troubled Trimel touts effect of its female sexual disorder drug Tefina. Report
Pharma News
@FiercePharma: Top-read Tues: With the Pfizer-AstraZeneca soap opera canceled, time for second-guessing. Story | Follow @FiercePharma
@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. Story | Follow @TracyStaton
@EricPFierce: ICYMI: Takeda now 5 for 6 in defending Actos cases at trial. Article | Follow @EricPFierce
@CarlyHFierce: GSK officially under investigation by Britain's Serious Fraud Office. Release | Follow @CarlyHFierce
> Cancer drugs beware: Docs to get monthly paybacks for sticking to preferred meds. More
> U.K. fraud police launch GlaxoSmithKline probe in wake of China corruption charges. Article
Drug Delivery News
> PolyTherics picks up Canadian delivery tech for targeted cancer treatment. Article
> Stentys releases data, says CE mark for sirolimus-eluting stent likely. More
> 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Story
> Mannkind: Approval of inhaled insulin drug around the corner. Report
> Swiss team develops imaging technique to aid drug delivery in constricted blood vessels. Item
Diagnostics News
> FDA OK's Qiagen companion Dx for use with Amgen colon cancer drug. News
> Roche, undaunted by reimbursement cutbacks, sees no need for Dx price reductions. Report
> In a first, Immucor wins FDA approval for a blood transfusion molecular Dx test. More
> iRhythm has CE mark in sight for arrhythmia Dx patch. Article
> Chinese scientists create viable paper Dx for hepatitis C virus. Story
Pharma Marketing News
> Sanofi, Lilly hook up to switch impotence remedy Cialis to OTC. Story
> J&J launches 'quantified self' app to game patients into better behavior. Article
> Takeda's colitis med Entyvio wins European OK on heels of FDA's approval. Item
> Sanofi's new MS med scores a spot on U.K.'s NHS formulary. More
> Pfizer, Forest and Lilly dominate top 10 ranking of psych meds. Story
> Got a problem, doc? In Eli Lilly's brave new sales world, that's a plus. Article